Patents Examined by Joanne Hama
-
Patent number: 11958899Abstract: Antibodies and antigen-binding fragments thereof that bind C1s and inhibit C1s activity and modulate the activity of at least one component in the classical pathway (CP) of complement activation, and methods for treating complement-mediated disorders using anti-C1s antibodies and fragments, are provided.Type: GrantFiled: June 28, 2022Date of Patent: April 16, 2024Inventors: Buxin Chen, Lei Huang, Xin Du
-
Patent number: 11807688Abstract: This invention relates to anti-AXL antibodies and methods of using them in treating diseases and conditions related to AXL activity, e.g., cancer.Type: GrantFiled: February 26, 2021Date of Patent: November 7, 2023Assignee: LES LABORATOIRES SERVIERInventors: Torben Gjetting, Trine Lindsted, Anton Willer, Anne Worsaae, Maria Carlsen Melander, Janus Schou Jakobsen, Randi Westh Hansen
-
Patent number: 11771737Abstract: In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of vancomycin and a checkpoint inhibitor. In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of a primary bile acid.Type: GrantFiled: October 29, 2018Date of Patent: October 3, 2023Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Tim F. Greten, Chi Ma
-
Patent number: 11773183Abstract: The present document describes an antibody or an antigen-binding fragment that bind to O-glycan mucin-type glycoprotein MUC16 comprising three variable heavy domain complementarity determining regions (CDR)(CDR H1, H2 and H3), and three variable lighy domain CDR (CDR L1, L2 and L3). The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of inhibiting tumor growth of a tumor expressing O-glycan mucin-type glycoprotein MUC16.Type: GrantFiled: April 30, 2019Date of Patent: October 3, 2023Assignee: QUEST PHARMATECH INC.Inventors: Ragupathy Madiyalakan, Michael Hollingsworth, Prakash Radhakrishnan
-
Patent number: 11766437Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.Type: GrantFiled: August 1, 2018Date of Patent: September 26, 2023Assignee: UNIVERSITY HEALTH NETWORKInventors: Mark Robert Bray, Jacqueline M. Mason, Tak W. Mak, Graham Fletcher
-
Patent number: 11739142Abstract: The present invention relates to bispecific anti-CCL2 antibodies binding to two different epitopes on human CCL2, pharmaceutical compositions thereof, their manufacture, and use as medicaments for the treatment of cancers, inflammatory, autoimmune and ophthalmologic diseases.Type: GrantFiled: December 16, 2020Date of Patent: August 29, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Jens Fischer, Guy Georges, Anton Jochner, Gregor Jordan, Hubert Kettenberger, Joerg Moelleken, Tilman Schlothauer, Georg Tiefenthaler, Valeria Runza, Meher Majety, Martin Schaefer, Maria Viert, Shu Feng, Wei Shiong Adrian Ho, Siok Wan Gan, Runyi Adeline Lam, Michael Gertz
-
Patent number: 11718671Abstract: Provided is a novel antibody and a method for treating breast cancer. More specifically, the present disclosure relates to a bispecific antibody targeting CD3 and a tumor antigen target such as HER2, a preparation method, and uses thereof. The present disclosure also relates to a composition containing said antibody and a method for treating cancer by using the antibody.Type: GrantFiled: January 7, 2019Date of Patent: August 8, 2023Assignee: Excelmab, Inc.Inventors: Wenjun Zhang, Cuijuan Chen, Xuemei Wei, Tonghui Luo
-
Patent number: 11708410Abstract: The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes TIGIT. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen-binding fragment thereof.Type: GrantFiled: January 15, 2019Date of Patent: July 25, 2023Assignee: Nanjing Legend Biotech Co., Ltd.Inventors: Xinpo Jiang, Shuai Yang, Chuan-Chu Chou
-
Patent number: 11692039Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human CD123 and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including Acute Myeloid Leukemia (AML) and myelodysplastic syndromes (MDS).Type: GrantFiled: December 30, 2021Date of Patent: July 4, 2023Inventors: Marielle Chiron, Angela Virone-Oddos, Laurent Gauthier
-
Patent number: 11685782Abstract: Provided herein are methods of treating cancer using LSD1 inhibitors in combination with immunotherapy.Type: GrantFiled: October 23, 2018Date of Patent: June 27, 2023Assignees: Children's Medical Center Corporation, President & Fellows of Harvard CollegeInventors: Yang Shi, Wanqiang Sheng, Arlene H. Sharpe, Martin W. LaFleur
-
Patent number: 11673934Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine and feline diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine or feline origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.Type: GrantFiled: September 29, 2021Date of Patent: June 13, 2023Assignee: Akston Biosciences CorporationInventors: Thomas M. Lancaster, Todd C. Zion
-
Patent number: 11655295Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.Type: GrantFiled: January 3, 2019Date of Patent: May 23, 2023Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.Inventors: Tongtong Xue, Qiang Li, Liang Xiao, Yuncheng Zheng, Dengnian Liu, Si Chen, Yan Hu, Lichun Wang, Jingyi Wang
-
Patent number: 11648274Abstract: The present invention provides a chimeric polypeptide comprising: an antigen-binding domain which constitutively binds to an ectodomain of a first chain of a cytokine receptor; a transmembrane domain; and an endodomain from a second chain of the cytokine receptor which chimeric polypeptide, when expressed in a cell, binds to the endogenous first chain of the cytokine receptor causing constitutive cytokine signalling.Type: GrantFiled: November 23, 2018Date of Patent: May 16, 2023Assignee: AUTOLUS LIMITEDInventors: Martin Pulé, Matteo Righi, Simon Thomas, Shimobi Onuoha, Shaun Cordoba
-
Patent number: 11649270Abstract: A T cell receptor (TCR) capable of specifically binding to a short peptide KASEKIFYV derived from an AFP antigen. The antigen short peptide KASEKIFYV can form a complex with HLA A0201 and be presented together with same to the cell surface. A nucleic acid molecule encoding the TCR, a vector comprising the nucleic acid molecule, and a cell that transduces the TCR.Type: GrantFiled: September 20, 2019Date of Patent: May 16, 2023Assignee: XLIFESC, LTD.Inventors: Yi Li, Jing Hu, Jun Li, Hanli Sun
-
Patent number: 11642379Abstract: The present invention provides clinical evidence for a method of stem cell transplantation that facilitates engraftment and reconstitutes immunocompetence of the recipient without requiring myeloablative conditioning.Type: GrantFiled: December 7, 2018Date of Patent: May 9, 2023Assignees: The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Rajni Agarwal, Janel Long Boyle, Morton J. Cowan, Christopher Dvorak, Hye Sook Kwon, Anne Le, Aaron Logan, Wendy Pang, Robertson Parkman, Maria-Grazia Roncarolo, Kenneth Weinberg, Judith A. Shizuru, Susan Sweeney Prohaska, Agnieszka Czechowicz, Irving L. Weissman
-
Patent number: 11623952Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-23, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1 comprises a sequence sharing 60% or greater sequence identity with SEQ ID NO: 1, CDR2 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 2 and CDR3 comprises a sequence sharing 50% or greater sequence identity with SEQ ID NO: 3.Type: GrantFiled: May 20, 2022Date of Patent: April 11, 2023Assignee: SORRISO PHARMACEUTICALS, INC.Inventors: Scott Crowe, Marion Cubitt, Tim Carlton, Luana Maggiore, Lurdes Duarte, Kevin Roberts, Mike West
-
Patent number: 11596655Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions for modulating the Natural Cyotoxicity Receptor 2 (NCR2).Type: GrantFiled: April 27, 2018Date of Patent: March 7, 2023Assignee: Washington UniversityInventors: Marco Colonna, Alexander David Barrow
-
Patent number: 11591389Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PAR2. In some embodiments, the anti-PAR2 antibodies or antigen-binding fragments thereof bind PAR2 in a pH-dependent manner. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.Type: GrantFiled: September 29, 2020Date of Patent: February 28, 2023Assignee: MEDIMMUNE LIMITEDInventors: Claire Dobson, Richard Williams, Ian Gurrell, Sadhana Podichetty, David Fairman, Peter Thornton, Philip Newton
-
Patent number: 11564946Abstract: Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.Type: GrantFiled: October 31, 2018Date of Patent: January 31, 2023Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Jacob Randolph Garcia, He Li
-
Patent number: 11559549Abstract: Provided herein are methods and compositions useful for treating PDL1 and/or PDL2 positive cancers through adoptive cell transfer of T cells genetically engineered to express a PD1-specific chimeric antigen receptor. Co-stimulatory domains such as Dap 10 may be included to enhance efficacy.Type: GrantFiled: September 26, 2018Date of Patent: January 24, 2023Assignee: LONGWOOD UNIVERSITYInventor: Amorette Barber